A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT ID: NCT06345729
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
600 participants
INTERVENTIONAL
2024-05-24
2031-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Hypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
NCT01840579
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
NCT07286149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MK-1084 with Pembrolizumab
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets until discontinuation criterion is met.
MK-1084
Oral tablets
Pembrolizumab
IV infusion
Placebo with Pembrolizumab
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met.
Placebo
Oral tablets
Pembrolizumab
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK-1084
Oral tablets
Placebo
Oral tablets
Pembrolizumab
IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
* Provides an archival tumor tissue sample (≤5 years) or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, PD-L1 status, and biomarker research
* If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to \< Grade 1 or baseline
* If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
* If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
* If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable
Exclusion Criteria
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
* Has known history of, or active, neurologic paraneoplastic syndrome
* Has an active infection requiring systemic therapy, with exceptions
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
* Has one or more of the following ophthalmological findings/conditions: intraocular pressure \>21 mmHg and/or any diagnosis of glaucoma, diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis of retinal degenerative disease
* Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC
* Has received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention
* Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis
* Has known active central nervous system metastases and/or carcinomatous meningitis
* Known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has active autoimmune disease that has required systemic treatment in the past 2 years
* Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has history of allogenic tissue/solid organ transplant
* Has not fully recovered from any effects of major surgical procedure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CBCC Global Research, Inc. ( Site 0123)
Bakersfield, California, United States
Beverly Hills Cancer Center ( Site 0116)
Beverly Hills, California, United States
Stamford Hospital ( Site 0136)
Stamford, Connecticut, United States
Mount Sinai Cancer Center ( Site 0137)
Miami Beach, Florida, United States
Orchard Healthcare Research Inc. ( Site 0115)
Skokie, Illinois, United States
Truman Medical Center ( Site 0126)
Kansas City, Missouri, United States
Cox Medical Center North ( Site 0133)
Springfield, Missouri, United States
St. Vincent Frontier Cancer Center-Research ( Site 0105)
Billings, Montana, United States
Atlantic Health System Morristown Medical Center ( Site 0121)
Morristown, New Jersey, United States
New York Oncology Hematology, P.C. ( Site 0132)
Albany, New York, United States
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
Cincinnati, Ohio, United States
Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)
Kettering, Ohio, United States
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)
Lancaster, Pennsylvania, United States
Oncology Consultants P.A. ( Site 0113)
Houston, Texas, United States
Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
Madison, Wisconsin, United States
AUSTRAL MEDICAL CENTER ( Site 0302)
CABA, Buenos Aires, Argentina
Centro Oncologico Korben ( Site 0304)
CABA, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)
Mar del Plata, Buenos Aires, Argentina
Sanatorio Parque ( Site 0301)
Rosario, Santa Fe Province, Argentina
Fundacion Estudios Clinicos ( Site 0306)
Rosario, Santa Fe Province, Argentina
Chris O'Brien Lifehouse ( Site 3000)
Camperdown, New South Wales, Australia
Frankston Hospital ( Site 3002)
Frankston, Victoria, Australia
One Clinical Research ( Site 3001)
Nedlands, Western Australia, Australia
Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)
Graz, Styria, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)
Vienna, , Austria
Hospital Mario Penna ( Site 0436)
Belo Horizonte, Minas Gerais, Brazil
Hospital de Câncer de Recife ( Site 0447)
Recife, Pernambuco, Brazil
Oncoclínica Oncologistas Associados ( Site 0441)
Teresina, Piauí, Brazil
Liga Norte Riograndense Contra o Câncer ( Site 0439)
Natal, Rio Grande do Norte, Brazil
Hospital de Caridade de Ijuí ( Site 0438)
Ijuí, Rio Grande do Sul, Brazil
Hospital de Clínicas de Passo Fundo ( Site 0442)
Passo Fundo, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)
Barretos, São Paulo, Brazil
Instituto Nacional de Câncer - INCA ( Site 0446)
Rio de Janeiro, , Brazil
Americas ( Site 0431)
Rio de Janeiro, , Brazil
MBAL Uni Hospital-Department of Medical Oncology ( Site 1000)
Panagyurishte, Pazardzhik, Bulgaria
Multiprofile Hospital for Active Treatment SerdikaМЕD EOOD-Second Department of Medical Oncology ( Site 1002)
Sofia, Sofia (stolitsa), Bulgaria
MHAT - Heart and Brain ( Site 1006)
Pleven, , Bulgaria
CancerCare Manitoba ( Site 0210)
Winnipeg, Manitoba, Canada
QEII Health Sciences Centre - Victoria General Site-Dept. of Medical Oncology ( Site 0208)
Halifax, Nova Scotia, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205)
Hamilton, Ontario, Canada
Sunnybrook Research Institute ( Site 0206)
Toronto, Ontario, Canada
St. Marys Hospital Center ( Site 0204)
Montreal, Quebec, Canada
Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207)
Trois-Rivières, Quebec, Canada
Clinica Universidad Catolica del Maule-Oncology ( Site 0500)
Talca, Maule Region, Chile
Orlandi Oncologia-Oncology ( Site 0503)
Santiago, Region M. de Santiago, Chile
FALP-UIDO ( Site 0501)
Santiago, Region M. de Santiago, Chile
Centro de Oncología de Precisión-Oncology ( Site 0502)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0504)
Santiago, Region M. de Santiago, Chile
Anhui Provincial Cancer Hospital ( Site 3136)
Hefei, Anhui, China
Beijing Cancer hospital ( Site 3133)
Beijing, Beijing Municipality, China
Beijing Cancer hospital ( Site 3134)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102)
Beijing, Beijing Municipality, China
Beijing Chest Hospital,Capital Medical University ( Site 3104)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital ( Site 3119)
Chongqing, Chongqing Municipality, China
Army Medical Center of People's Liberation Army ( Site 3142)
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital ( Site 3127)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University ( Site 3148)
Xiamen, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University ( Site 3108)
Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital ( Site 3128)
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center ( Site 3137)
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital ( Site 3123)
Harbin, Heilongjiang, China
JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124)
Jiamusi, Heilongjiang, China
Henan Cancer Hospital ( Site 3149)
Zhengzhou, Henan, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 3113)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 3126)
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University ( Site 3130)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 3141)
Changsha, Hunan, China
Nanjing Gulou Hospital ( Site 3122)
Nanjing, Jiangsu, China
Nanjing First Hospital ( Site 3154)
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University ( Site 3146)
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155)
Wuxi, Jiangsu, China
The Second Affiliated Hospital of Nanchang University ( Site 3139)
Nanchang, Jiangxi, China
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138)
Nanchang, Jiangxi, China
Jilin Province Tumor Hospital ( Site 3107)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150)
Xi'an, Shaanxi, China
Shandong Cancer Hospital ( Site 3116)
Jinan, Shandong, China
LinYi Cancer Hospital ( Site 3111)
Linyi, Shandong, China
Shanghai Chest Hospital ( Site 3100)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center ( Site 3144)
Shanghai, Shanghai Municipality, China
Zhongshan Hospital,Fudan University ( Site 3143)
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital ( Site 3131)
Taiyuan, Shanxi, China
The Second Affiliated Hospital of Air Force Medical University ( Site 3117)
Xian, Shanxi, China
The Second Affiliated Hospital of Air Force Medical University ( Site 3152)
Xian, Shanxi, China
The Third People's Hospital of Chengdu (CDTPH) ( Site 3157)
Chengdu, Sichuan, China
West China Hospital, Sichuan University ( Site 3140)
Chengdu, Sichuan, China
Sichuan Cancer hospital. ( Site 3109)
Chengdu, Sichuan, China
The Second People's Hospital of Neijiang ( Site 3105)
Neijiang, Sichuan, China
Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101)
Ürümqi, Xinjiang, China
Yunnan Province Cancer Hospital ( Site 3153)
Kunming, Yunnan, China
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121)
Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province ( Site 3145)
Linhai, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 3151)
Wenzhou, Zhejiang, China
Tokyo Medical University Hospital ( Site 3307)
Shinjuku, Tokyo, Japan
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1103)
Dijon, Bourgogne-Franche-Comté, France
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 1106)
Nîmes, Gard, France
Clinique Teissier Groupe ( Site 1100)
Valenciennes, Nord, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101)
Clermont-Ferrand, Puy-de-Dome, France
Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1104)
Avignon, Vaucluse, France
Hôpital Ambroise Paré-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105)
Boulogne-Billancourt, Île-de-France Region, France
High Technology Hospital Medcenter ( Site 1203)
Batumi, Adjara, Georgia
Caucasus Medical Centre ( Site 1202)
Tbilisi, Adjara, Georgia
American Hospital Network LLC ( Site 1208)
Tbilisi, , Georgia
Todua Clinic, LLC ( Site 1204)
Tbilisi, , Georgia
TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201)
Tbilisi, , Georgia
New Hospitals ( Site 1200)
Tbilisi, , Georgia
Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205)
Tbilisi, , Georgia
Tbilisi Institute of Medicine ( Site 1206)
Tbilisi, , Georgia
Marienhospital Stuttgart ( Site 1302)
Stuttgart, Baden-Wurttemberg, Germany
Krankenhaus Bethanien ( Site 1303)
Solingen, North Rhine-Westphalia, Germany
UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402)
Pátrai, Achaia, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400)
Athens, Attica, Greece
University General Hospital of Larissa-Oncology Clinic ( Site 1403)
Larissa, Thessaly, Greece
Agios Loukas Clinic ( Site 1404)
Thessaloniki, , Greece
G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405)
Thessaloniki, , Greece
Sir H. N. Reliance Foundation Hospital and Research Centre ( Site 3201)
Mumbai, Maharashtra, India
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607)
Napoli, Campania, Italy
Ospedale Santa Maria delle Croci ( Site 1606)
Ravenna, Emilia-Romagna, Italy
CRO-IRCCS-Clinical Oncology ( Site 1605)
Aviano, Friuli Venezia Giulia, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601)
Rome, Lazio, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1600)
Milan, Lombardy, Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604)
Milan, Lombardy, Italy
A.O.R.N. Ospedale dei Colli - Monaldi V.-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1602)
Naples, Napoli, Italy
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609)
Rome, Roma, Italy
Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608)
Livorno, Tuscany, Italy
IOV - Istituto Oncologico Veneto IRCCS UOSD - Unità di ricerca clinica ( Site 1603)
Padua, , Italy
Nagoya University Hospital ( Site 3309)
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital ( Site 3310)
Toyoake, Aichi-ken, Japan
National Hospital Organization Shikoku Cancer Center ( Site 3315)
Matsuyam, Ehime, Japan
National Hospital Organization Kyushu Cancer Center ( Site 3316)
Fukuoka, Fukuoka, Japan
Kurume University Hospital ( Site 3317)
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center ( Site 3302)
Ōta, Gunma, Japan
Kanazawa University Hospital ( Site 3308)
Kanazawa, Ishikawa-ken, Japan
St. Marianna University Hospital ( Site 3320)
Kawasaki, Kanagawa, Japan
Matsusaka Municipal Hospital ( Site 3311)
Matsusaka, Mie-ken, Japan
Miyagi Cancer Center ( Site 3301)
Natori-shi, Miyagi, Japan
Sendai Kousei Hospital ( Site 3300)
Sendai, Miyagi, Japan
Kansai Medical University Hospital ( Site 3312)
Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital ( Site 3313)
Takatsuki, Osaka, Japan
Saitama Prefectural Cancer Center ( Site 3304)
Kitaadachi-gun, Saitama, Japan
Nippon Medical School Hospital ( Site 3306)
Bunkyo, Tokyo, Japan
Toho University Omori Medical Center ( Site 3319)
Ōta-ku, Tokyo, Japan
National Center for Global Health and Medicine ( Site 3305)
Shinjuku, Tokyo, Japan
Chiba University Hospital ( Site 3322)
Chiba, , Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 3314)
Hiroshima, , Japan
Saiseikai Kumamoto Hospital ( Site 3318)
Kumamoto, , Japan
Niigata University Medical & Dental Hospital ( Site 3323)
Niigata, , Japan
Osaka Metropolitan University Hospital ( Site 3321)
Osaka, , Japan
Arké SMO S.A. de C.V. ( Site 0602)
Mexico City, Mexico City, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0600)
Monterrey, Nuevo León, Mexico
Oaxaca Site Management Organization S.C. ( Site 0603)
Oaxaca City, , Mexico
Ziekenhuis Gelderse Vallei ( Site 1705)
Ede, Gelderland, Netherlands
Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701)
Harderwijk, Gelderland, Netherlands
Isala, locatie Zwolle-Poli Longziekten ( Site 1700)
Zwolle, Overijssel, Netherlands
Universitair Medisch Centrum Utrecht ( Site 1704)
Utrecht, , Netherlands
Auckland City Hospital ( Site 3400)
Auckland, , New Zealand
The Medical City ( Site 3507)
Pasig, National Capital Region, Philippines
Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503)
Quezon City, National Capital Region, Philippines
Veterans Memorial Medical Center-Section of Oncology ( Site 3505)
Quezon City, National Capital Region, Philippines
ST. LUKE'S MEDICAL CENTER-Medical oncology ( Site 3501)
Quezon City, National Capital Region, Philippines
Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1801)
Gorlice, Lesser Poland Voivodeship, Poland
Pratia MCM Krakow ( Site 1808)
Krakow, Lesser Poland Voivodeship, Poland
Uniwersytecki Szpital Kliniczny nr 4 w Lublinie ( Site 1805)
Lublin, Lublin Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1800)
Warsaw, Masovian Voivodeship, Poland
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1804)
Przemyśl, Podkarpackie Voivodeship, Poland
Centrul de Diagnostic si Tratament Provita. ( Site 1992)
Bucharest, București, Romania
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994)
Craiova, Dolj, Romania
Cabinet Medical Oncomed ( Site 1998)
Timișoara, Timiș County, Romania
SC ONCO CARD SRL ( Site 1995)
Brasov, , Romania
Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999)
Cluj-Napoca, , Romania
Sigmedical Services SRL ( Site 1997)
Suceava, , Romania
The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606)
Bupyeong-gu, Incheon, South Korea
Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604)
Hwasun, Jeonranamdo, South Korea
The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600)
Suwon, Kyonggi-do, South Korea
Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603)
Yangsan, Kyongsangnam-do, South Korea
Chungnam national university hospital ( Site 3602)
Junggu, Taejon-Kwangyokshi, South Korea
Kyung Hee University Hospital ( Site 3605)
Seoul, , South Korea
Korea University Guro Hospital ( Site 3601)
Seoul, , South Korea
Hospital Insular de Gran Canaria-Oncology ( Site 2019)
Las Palmas de Gran Canaria, Las Palmas, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2012)
Madrid, Madrid, Comunidad de, Spain
H.R.U Málaga - Hospital General-Oncology ( Site 2014)
Málaga, Malaga, Spain
Hospital Universitari Vall d Hebron ( Site 2010)
Barcelona, , Spain
Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2017)
Madrid, , Spain
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2015)
Seville, , Spain
Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2102)
Bornova, İzmir, Turkey (Türkiye)
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107)
Adana, , Turkey (Türkiye)
SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104)
Ankara, , Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101)
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 2106)
Ankara, , Turkey (Türkiye)
Ankara Bilkent Şehir Hastanesi ( Site 2100)
Ankara, , Turkey (Türkiye)
Medipol Mega Universite Hastanesi-oncology ( Site 2105)
Istanbul, , Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2103)
Istanbul, , Turkey (Türkiye)
COMMUNAL NONPROFIT ENTERPRISE "CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209)
Cherkasy, Cherkasy Oblast, Ukraine
Regional Municipal Non-profit Enterprise "Bukovinian Clinica-structural unit of the clinical trials ( Site 2210)
Chernivtsi, Chernivetska Oblast, Ukraine
Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2215)
Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 2202)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204)
Kropyvnytskyi, Kirovohrad Oblast, Ukraine
Medical Center "MedOffice Group" ( Site 2219)
Kiev, Kyivska Oblast, Ukraine
Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 2217)
Lviv, Lviv Oblast, Ukraine
Rivne Regional Clinical Hospital ( Site 2205)
Rivne, Rivne Oblast, Ukraine
ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2920)
Rivne, Rivne Oblast, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 2211)
Vinnytsia, Vinnytsia Oblast, Ukraine
ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216)
Lutsk, Volyn Oblast, Ukraine
Milton Keynes Hospital ( Site 2304)
Milton Keynes, Buckinghamshire, United Kingdom
Royal Devon & Exeter Hospital-Oncology ( Site 2302)
Exeter, Devon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-1084-004
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1296-8093
Identifier Type: REGISTRY
Identifier Source: secondary_id
2023-507776-42-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
jRCT2031240213
Identifier Type: REGISTRY
Identifier Source: secondary_id
PHRR241128-007796
Identifier Type: REGISTRY
Identifier Source: secondary_id
KANDLELIT-004
Identifier Type: OTHER
Identifier Source: secondary_id
1084-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.